Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000899243-21-032755

Chief Scientific Officer sold 51,785 shares at an average $17.60 ($911,416)

  • Chief Scientific Officer acquired 51,785 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Moxham Christopher · Chief Scientific Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2021-08-10 Exercise or conversion : show line 1 in the form +20,714 $7.84 $162,398 20,714 D
2021-08-10 Sale : show line 2 in the form −20,714 $17.00 $352,138 0 D
2021-08-10 Exercise or conversion : show line 3 in the form +31,071 $7.84 $243,597 31,071 D
2021-08-10 Sale : show line 4 in the form −31,071 $18.00 $559,278 0 D
Open-market sales · 51,785 sh · avg $17.60 · $911,416

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2021-08-10 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −20,714 103,572 D
2021-08-10 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −31,071 72,501 D
Loading xslF345X03/doc4.xml…